US EditionMakary Faces Pressure Over Abortion Pill After Study Finds Risks
- A study published on Monday, April 28, 2025, by a policy research organization reported that nearly 11% of women in the US taking mifepristone experienced serious adverse effects.
- This study followed FDA data that reported less than 0.5% serious reactions and reflects growing concerns amid increased chemical abortions since 2017 and state-level abortion regulation changes.
- An independent analysis conducted alongside the Ethics and Public Policy Center’s study affirmed these results, indicating that the actual complication rate exceeds the FDA’s label estimates by more than 22-fold.
- Senator Josh Hawley from Missouri called FDA Commissioner Martin Makary's pledge to take no immediate action on mifepristone "exceptionally disappointing," urging prompt reconsideration based on new data.
- These developments imply regulatory review may intensify, potentially reinstating safety controls on mifepristone usage as Makary acknowledged evolving decisions depending on emerging evidence.
9 Articles
9 Articles
New Abortion Pill Complication Research Challenges FDA Commissioner’s Disinterest in Restrictions | The Star News Network
by Greg Piper Pro-life pregnancy centers are fighting Democratic attorneys general in court for the right to tell women they may be able to reverse chemical abortions by taking supplemental progesterone, a natural pregnancy hormone, to prevent mifepristone from binding to pregnancy receptors. New York’s Letitia James is now trying to overturn an injunction against her. Texas Republican AG Ken Paxton secured a $100,000 judgment against a New Yo…
New Abortion Pill Complication Research Challenges FDA Commissioner's Disinterest in Restrictions - The Florida Capital Star
by Greg Piper Pro-life pregnancy centers are fighting Democratic attorneys general in court for the right to tell women they may be able to reverse chemical abortions by taking supplemental progesterone, a natural pregnancy hormone, to prevent mifepristone from binding to pregnancy receptors. New York’s Letitia James is now trying to overturn an injunction against her. Texas Republican AG Ken Paxton secured a $100,000 judgment against a New Yo…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
